Quick Answer
ACTUATE THERAPEUTICS, INC. reported Earnings Per Share Diluted of $1.06 (loss) per share for the year ending 2025.
- ACTUATE THERAPEUTICS, INC. showed an increase of +67.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from ACTUATE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $3.88 (loss) per share | Q3 2023: $4.31 (loss) per share | Q1 2024: $5.40 (loss) per share | Q2 2024: $4.20 (loss) per share | Q3 2024: $0.55 (loss) per share | Q1 2025: $0.32 (loss) per share | Q2 2025: $0.30 (loss) per share | Q3 2025: $0.25 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), ACTUATE THERAPEUTICS, INC.'s Earnings Per Share Diluted has grown by 93.9%.
- Historical annual values: Fiscal year 2025: $1.06 (loss) per share | Fiscal year 2024: $3.26 (loss) per share | Fiscal year 2023: $17.24 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: